FORE Biotherapeutics

Recent Finacing

Series D

Recent Raise

$75M

FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.